Trigyn Technologies Limited
Trigyn Technologies Limited Fundamental Analysis
Trigyn Technologies Limited (TRIGYN.NS) shows weak financial fundamentals with a PE ratio of 42.67, profit margin of 0.41%, and ROE of 0.53%. The company generates $9.7B in annual revenue with weak year-over-year growth of -29.82%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -29.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze TRIGYN.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakTRIGYN.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateTRIGYN.NS shows balanced valuation metrics.
Growth Score
WeakTRIGYN.NS faces weak or negative growth trends.
Financial Health Score
ExcellentTRIGYN.NS maintains a strong and stable balance sheet.
Profitability Score
WeakTRIGYN.NS struggles to sustain strong margins.
Key Financial Metrics
Is TRIGYN.NS Expensive or Cheap?
P/E Ratio
TRIGYN.NS trades at 42.67 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, TRIGYN.NS's PEG of -3.61 indicates potential undervaluation.
Price to Book
The market values Trigyn Technologies Limited at 0.22 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 26.38 times EBITDA. This signals the market has high growth expectations.
How Well Does TRIGYN.NS Make Money?
Net Profit Margin
For every $100 in sales, Trigyn Technologies Limited keeps $0.41 as profit after all expenses.
Operating Margin
Core operations generate 0.16 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.53 in profit for every $100 of shareholder equity.
ROA
Trigyn Technologies Limited generates $0.43 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Trigyn Technologies Limited generates limited operating cash flow of $-614.03M, signaling weaker underlying cash strength.
Free Cash Flow
Trigyn Technologies Limited generates weak or negative free cash flow of $-622.21M, restricting financial flexibility.
FCF Per Share
Each share generates $-20.21 in free cash annually.
FCF Yield
TRIGYN.NS converts -37.11% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
42.67
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.61
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.22
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.17
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.009
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.25
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.005
vs 25 benchmark
ROA
Return on assets percentage
0.004
vs 25 benchmark
ROCE
Return on capital employed
0.002
vs 25 benchmark
How TRIGYN.NS Stacks Against Its Sector Peers
| Metric | TRIGYN.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 42.67 | 33.97 | Worse (Expensive) |
| ROE | 0.53% | 1021.00% | Weak |
| Net Margin | 0.41% | 5902824510.00% | Weak |
| Debt/Equity | 0.01 | 0.45 | Strong (Low Leverage) |
| Current Ratio | 5.25 | 6.06 | Strong Liquidity |
| ROA | 0.43% | -293849.00% (disorted) | Weak |
TRIGYN.NS outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Trigyn Technologies Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-1.45%
Industry Style: Growth, Innovation, High Beta
DecliningEPS CAGR
-76.53%
Industry Style: Growth, Innovation, High Beta
DecliningFCF CAGR
5073.97%
Industry Style: Growth, Innovation, High Beta
High Growth